Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) D

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the sale, the director now owns 255,253 […]

Related Keywords

Canada , Franzb Humer , Piper Sandler , Canada Life Assurance , Pricet Rowe Associates Inc , Allogene Therapeutics Company Profile , Nasdaq , Allogene Therapeutics Inc , Susquehanna Fundamental Investments , Jpmorgan Chase Co , Securities Exchange Commission , Headlands Technologies , Mirae Asset Global Investments Co , Allogene Therapeutics , Get Free Report , Director Franz , Exchange Commission , Fundamental Investments , Mirae Asset Global Investments , Asset Global Investments , Allogene Therapeutics Daily ,